[go: up one dir, main page]

WO2025008516A3 - Indole derivatives with factor b inhibitory activity - Google Patents

Indole derivatives with factor b inhibitory activity Download PDF

Info

Publication number
WO2025008516A3
WO2025008516A3 PCT/EP2024/069024 EP2024069024W WO2025008516A3 WO 2025008516 A3 WO2025008516 A3 WO 2025008516A3 EP 2024069024 W EP2024069024 W EP 2024069024W WO 2025008516 A3 WO2025008516 A3 WO 2025008516A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
inhibitory activity
indole derivatives
compounds
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/069024
Other languages
French (fr)
Other versions
WO2025008516A2 (en
Inventor
John Andrew Christopher
Paul Graham Wyatt
Thomas William HORNSBY
Martin Edward Cooper
Mark Mills
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sitala Bio Ltd
Original Assignee
Sitala Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2316974.1A external-priority patent/GB202316974D0/en
Application filed by Sitala Bio Ltd filed Critical Sitala Bio Ltd
Publication of WO2025008516A2 publication Critical patent/WO2025008516A2/en
Publication of WO2025008516A3 publication Critical patent/WO2025008516A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to active esters of Factor B inhibitors, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.
PCT/EP2024/069024 2023-07-06 2024-07-05 Novel compounds Pending WO2025008516A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202310422 2023-07-06
GB2310422.7 2023-07-06
GB2316974.1 2023-11-06
GBGB2316974.1A GB202316974D0 (en) 2023-11-06 2023-11-06 Novel compounds

Publications (2)

Publication Number Publication Date
WO2025008516A2 WO2025008516A2 (en) 2025-01-09
WO2025008516A3 true WO2025008516A3 (en) 2025-02-13

Family

ID=91899194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/069024 Pending WO2025008516A2 (en) 2023-07-06 2024-07-05 Novel compounds

Country Status (1)

Country Link
WO (1) WO2025008516A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009616A1 (en) * 2013-07-15 2015-01-22 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027113B1 (en) 2012-05-04 2017-06-30 Новартис Аг Complement pathway modulators and uses thereof
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN105229003B (en) 2013-03-14 2017-03-15 诺华股份有限公司 2- (1H-indol-4-ylmethyl) -3H-imidazo [4,5-B ] pyridine-6-carbonitrile derivatives as complement factor B inhibitors for the treatment of ophthalmic diseases
CN114057692B (en) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 Heterocyclic compound, preparation method and application thereof
IL300432A (en) 2020-08-07 2023-04-01 Shanghai Meiyue Biotech Dev Co Ltd Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
KR20230128039A (en) 2020-12-30 2023-09-01 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Nitrogen-containing bridged heterocyclic compound, its preparation method and its medical use
CA3203447A1 (en) 2020-12-30 2022-07-07 Kevin X Chen Series of piperidine-substituted benzoic acid compounds, and use thereof
CA3205097A1 (en) 2021-01-14 2022-07-21 Jason Allan Wiles Macrocycle complement factor b inhibitors
US20240217953A1 (en) 2021-04-16 2024-07-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
PE20250114A1 (en) 2021-06-03 2025-01-16 Chinook Therapeutics Inc SUBSTITUTED INDOL COMPOUNDS AND METHODS OF USING THEM
US20240360103A1 (en) 2021-06-30 2024-10-31 Apellis Pharmaceuticals, Inc. Complement inhibition
JP2024532847A (en) 2021-08-18 2024-09-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Benzazepine aromatic ring derivatives and their medical applications
MX2024004921A (en) 2021-10-27 2024-06-19 Hansoh Bio Llc PIPERIDINILINDOL DERIVATIVES, METHODS OF PREPARATION AND MEDICINAL USES OF THESE.
IL314186A (en) 2022-01-24 2024-09-01 Novartis Ag PIPERIDINYL SPIROCYCLIC DERIVATIVES AS COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
WO2024049977A1 (en) 2022-08-31 2024-03-07 Chinook Therapeutics, Inc. Substituted indole compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009616A1 (en) * 2013-07-15 2015-01-22 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors

Also Published As

Publication number Publication date
WO2025008516A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
CR20230310A (en) Prmt5 inhibitors
MX2023009222A (en) Tricyclic-amido-bicyclic prmt5 inhibitors.
MY210283A (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
MX2021004431A (en) Novel processes.
MX2024007058A (en) 5,6,7,8-tetrahydro-2,6-naphthyridine derivatives as cancer therapeutics.
WO2019195720A8 (en) Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
MX2022013482A (en) Compounds useful for inhibiting ret kinase.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2025005941A (en) Modulators of tnf-î± activity
PH12022550790A1 (en) Oral complement factor d inhibitors
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors
WO2025008516A3 (en) Indole derivatives with factor b inhibitory activity
WO2024189598A3 (en) Acylsulfonamide kat6a inhibitors
TN2022000095A1 (en) Oral complement factor d inhibitors
MX2025001865A (en) Substituted pyridinone compounds as cbl-b inhibitors
MX2023007150A (en) Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2024026481A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
MX2022006052A (en) Caspase 6 inhibitors and uses thereof.
WO2017029588A3 (en) Mdm2 inhibitors for treating uveal melanoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24740851

Country of ref document: EP

Kind code of ref document: A2